Circulating biomarkers for monitoring therapy response and detection of disease progression in lung cancer patients

Autor: Ben van den Borne, Luc Brunsveld, Marleen E A de Saegher, Huub Belderbos, Claartje van Dongen-Schrover, Volkher Scharnhorst, Remco de Kock, Sylvia Genet, Gerben Stege, Birgit Deiman, Maggy Youssef El Soud
Přispěvatelé: Chemical Biology, Eindhoven MedTech Innovation Center, ICMS Core, EAISI Health
Rok vydání: 2021
Předmět:
Male
0301 basic medicine
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Therapy response monitoring
Cell
SDG 3 – Goede gezondheid en welzijn
NSCLC
medicine.disease_cause
Gastroenterology
03 medical and health sciences
0302 clinical medicine
SDG 3 - Good Health and Well-being
Early detection disease progression
Internal medicine
Biomarkers
Tumor
medicine
Humans
Digital polymerase chain reaction
Prospective Studies
Liquid biopsy
Lung cancer
RC254-282
Aged
Circulating tumor DNA
business.industry
Liquid Biopsy
Protein tumor markers
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Middle Aged
medicine.disease
030104 developmental biology
Therapy response
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Disease Progression
Biomarker (medicine)
Female
KRAS
business
Progressive disease
Zdroj: Cancer Treatment and Research Communications, Vol 28, Iss, Pp 100410-(2021)
Cancer Treatment and Research Communications, 28:100410. Elsevier
ISSN: 2468-2942
DOI: 10.1016/j.ctarc.2021.100410
Popis: Liquid biopsies have become of interest as minimally invasive ways to monitor treatment response in lung cancer patients. Circulating tumor DNA (ctDNA) and protein biomarkers are evaluated for their added value in monitoring therapy response and early detection of disease progression. Plasma and serum samples of non-small cell or small cell lung cancer patients were analyzed for driver mutations in ctDNA (EGFR, KRAS or BRAF) using droplet digital PCR and protein biomarkers (CA125, CEA, CA15.3, Cyfra 21-1, HE4, NSE, proGRP and SCCA) using electrochemiluminescence immunoassays. Biomarker concentration changes were compared with the outcome of CT-scans during therapy. The median difference of the concentration of ctDNA, CA125 and Cyfra21-1 was significantly lower in patients with partial response (PR) compared to patients with progressive disease (PD) on the first evaluation CT-scan (P
Databáze: OpenAIRE
Externí odkaz: